The FDA has granted approval for a new pneumococcal 20-valent conjugate vaccine that can protect against 20 serotypes associated with most cases of invasive pneumococcal disease (IPD) and pneumonia. 

PREVNAR 20 includes an additional seven serotypes accountable for a little less than half of all US cases of pneumococcal disease and deaths linked with it. The approval is based on positive results from three late-stage trials showing the vaccines safety and immunogenicity, which included over 6000 vaccine-naive adults as well as adults with previous pneumococcal vaccination. Compared to the currently available pneumococcal vaccine PCV13, this new vaccine protects against seven additional serotypes, including 8, 10A, 11A, 12F, 15B, 22F, and 33F… (Medscape)